{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:37:22Z","timestamp":1778575042999,"version":"3.51.4"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Udenafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for the treatment of erectile dysfunction (ED).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This study was performed to evaluate the efficacy and safety of udenafil therapy in patients with ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this multicenter, double-blind, placebo-controlled, fixed-dose, parallel-group phase III trial, 167 patients with ED of diverse origin and severity were randomized to take placebo or udenafil at fixed doses of 100 or 200 mg as needed for 12 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Primary efficacy variable was change from baseline in erectile function (EF) domain scores of the International Index of Erectile Dysfunction (IIEF) questionnaire. Secondary efficacy variables include change from baseline in scores on the IIEF Questions 3 and 4 (IIEF Q3 and Q4), change from baseline in all domain scores of the IIEF, patients' responses to questions 2 and 3 of the Sexual Encounter Profile (SEP2 and SEP3), and patients' responses to the Global Assessment Question (GAQ). Any adverse events were also recorded during the trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After 12 weeks of treatment, the patients treated with udenafil showed significantly greater change from baseline in the IIEF-EF domain score compared with placebo (placebo, 0.20; 100-mg udenafil, 7.52; and 200-mg udenafil, 9.93, respectively) (P &amp;lt;0.0001). Compared with placebo, udenafil significantly enhanced the rates of successful penetration (SEP Q2) and maintenance of erection (SEP Q3) (P &amp;lt;0.0001). Furthermore, significantly greater proportions of udenafil treatment groups responded positively to the GAQ compared with the placebo group (GAQ: placebo, 25.9%; 100-mg udenafil, 81.5%; and 200-mg udenafil, 88.5%, respectively) (P &amp;lt;0.0001). Treatment-related adverse events were generally mild to moderate with facial flushing and headache being the most common.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Udenafil is an effective and well-tolerated therapy for ED of broad-spectrum etiology and severity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2007.00723.x","type":"journal-article","created":{"date-parts":[[2008,3,26]],"date-time":"2008-03-26T10:29:25Z","timestamp":1206527365000},"page":"946-953","source":"Crossref","is-referenced-by-count":60,"title":["The Efficacy and Safety of Udenafil, a New Selective Phosphodiesterase Type 5 Inhibitor, in Patients with Erectile Dysfunction"],"prefix":"10.1093","volume":"5","author":[{"given":"Jae-Seung","family":"Paick","sequence":"first","affiliation":[{"name":"Department of Urology, Seoul National University Hospital , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae Woong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Urology, St Mary's Hospital , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Yeol","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hallym Medical Center , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Jong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Urology, Korea University Hospital , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, Samsung Medical Center , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai Young","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Urology, Asan Medical Center , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung Ki","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Urology, Youngdong Severance Hospital , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Kyu","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Urology, Inha University Hospital , Incheon , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae Chul","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Urology, Chung-Ang University Medical Center , Seoul , Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,4,1]]},"reference":[{"key":"2024032523572510400_bib1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1517\/13543784.11.11.1605","article-title":"Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction","volume":"11","author":"Kuan","year":"2002","journal-title":"Expert Opin Invest Drugs"},{"key":"2024032523572510400_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1464-410X.2005.05614.x","article-title":"Phosphodiesterase type 5 inhibitors for erectile dysfunction","volume":"96","author":"Carson","year":"2005","journal-title":"BJU Int"},{"key":"2024032523572510400_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/BF02977007","article-title":"Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159","volume":"25","author":"Doh","year":"2002","journal-title":"Arch Pharm Res"},{"key":"2024032523572510400_bib4","first-page":"661","article-title":"Drug evaluation: Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction","volume":"7","author":"Salem","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"2024032523572510400_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.clpt.2003.11.330","article-title":"DA-8159-phase I studies to investigate the safety and pharmacokinetics in healthy male Caucasian subjects","volume":"75","author":"Amakye","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"2024032523572510400_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0090-4295(99)00099-0","article-title":"Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function","volume":"54","author":"Cappelleri","year":"1999","journal-title":"Urology"},{"key":"2024032523572510400_bib7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"2024032523572510400_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.ijir.3900857","article-title":"The International Index of Erectile Function (IIEF): A state-of-the-science review","volume":"14","author":"Rosen","year":"2002","journal-title":"Int J Impot Res"},{"key":"2024032523572510400_bib9","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","article-title":"Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses","volume":"168","author":"Brock","year":"2002","journal-title":"J Urol"},{"key":"2024032523572510400_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1743-6109.2007.00468.x","article-title":"The efficacy and safety of vardenafil in East Asian men with erectile dysfunction","volume":"4","author":"Chen","year":"2007","journal-title":"J Sex Med"},{"key":"2024032523572510400_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.ijir.3900631","article-title":"On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction","volume":"13","author":"Padma-Nathan","year":"2001","journal-title":"Int J Impot Res"},{"key":"2024032523572510400_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.ju.0000063377.12281.57","article-title":"Deciphering erectile dysfunction drug trials","volume":"170","author":"Mulhall","year":"2003","journal-title":"J Urol"},{"key":"2024032523572510400_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1939-4640.2002.tb02332.x","article-title":"Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Hellstrom","year":"2002","journal-title":"J Androl"},{"key":"2024032523572510400_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1464-410X.2004.05049.x","article-title":"Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction","volume":"94","author":"Eardley","year":"2004","journal-title":"BJU Int"},{"key":"2024032523572510400_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1743-6109.2006.00380.x","article-title":"Vardenafil restores erectile function to normal range in men with erectile dysfunction","volume":"4","author":"Padma-Nathan","year":"2007","journal-title":"J Sex Med"},{"key":"2024032523572510400_bib16","first-page":"820","article-title":"Erectile dysfunction. New drugs with special consideration of the PDE5 inhibitors","volume":"43","author":"Porst","year":"2004","journal-title":"Urologe A"},{"key":"2024032523572510400_bib17","first-page":"98","article-title":"Ocular adverse effects of sildenafil","volume":"12","year":"2003","journal-title":"Prescrire Int"},{"key":"2024032523572510400_bib18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1743-6109.2006.00273.x","article-title":"Efficacy of tadalafil in men with erectile dysfunction naive to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate","volume":"3","author":"Broderick","year":"2006","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515319858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515319858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/5\/4\/946\/47512081\/jsm_5_4_946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/5\/4\/946\/47512081\/jsm_5_4_946.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:50:53Z","timestamp":1711414253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/5\/4\/946\/6862396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2008,4,1]]},"published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2007.00723.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2008,4]]},"published":{"date-parts":[[2008,4,1]]}}}